Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
February 2018

Recent Stories

From Specialty Pharmacy News - When the FDA approved the third gene therapy ever last month, a product to treat a rare form of blindness, industry watchers hailed the agency for the move. But while it may be difficult to put a price tag on a cure for blindness, Spark Therapeutics, Inc. priced Luxturna (voretigene neparvovec-rzyl) at $425,000 per eye, or $850,000 total for the one-time therapy. Read more

An earlier version of this story incorrectly said that the FDA approved… Read more

About 10 months after issuing final guidance calling for all biologics to… Read more

Although the planned CVS Health Corp. acquisition of Aetna Inc. may have… Read more

From the Editor

Welcome to Your Radar on Specialty Pharmacy Subscriber Website

Exclusively for subscribers to Radar on Specialty Pharmacy (formerly Specialty Pharmacy News), this website is your source for PDFs of back issues, archives of articles and data, and more!

Please e-mail me with comments on the latest issue, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

January 10, 2018
Specialty Pharmacy News is about to become Radar on Specialty Pharmacy

With the February issue of SPN, we will adopt a new publication name: Radar on Specialty Pharmacy. While our focus is still squarely on providing strategies and analysis for managing high-cost specialty products, our new name signals a renewed commitment to in-depth, forward-looking coverage. Every issue will bring incisive coverage of the companies, people, catalysts and trends that shape the pharma industry today and in the future.

Radar on Specialty Pharmacy will join our other newly named publications: Radar on Medicare Advantage (formerly Medicare Advantage News) and Radar on Drug Benefits (formerly Drug Benefit News), available alongside Health Plan Weekly and Health Business Daily. Visit the AISHealth Marketplace for more information about our publications.

November 16, 2017
FDA Begins Implementing Naming Guidance

The FDA has started adding 4-letter suffixes to non-biosimilar biologics per its January final guidance: Mepsevii (vestronidase alfa-vjbk) and Hemlibra (emicizumab-kxwh)

August 30, 2017
First Gene Therapy Gets FDA Approval

FDA approves first gene therapy in U.S., Novartis’ CAR-T drug Kymriah, for treatment of people up to 25 years old with B-cell precursor acute lymphoblastic leukemia that is refractory or has relapsed at least twice http://tinyurl.com/y8xku8ol

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?